POLYMERASE CHAIN REACTIONASSAY FOR DELTA LF IN CANCER

乳铁蛋白是一种铁结合蛋白，存在于牛奶和各种 分泌物，已经作为一种参与宿主的多功能蛋白质出现 对感染和肿瘤的防御。我们最近确认了 LFmRNA的另一种形式，我们称之为ALF。尽管如此，我们发现ALF基因在 100%(30/30)的正常人体组织中，仅有10%(3/30)的组织中有ALF基因的表达 28)肿瘤来源的细胞系多样化。在初步研究中，我们发现 90%(9/10)乳腺原发肿瘤组织中ALF mRNA表达水平降低 与正常的人类乳房组织相比。在第一阶段，我们计划制定一项 定量RT-PCR检测LFmRNA和LFmRNA的表达。到时候我们会的 142例ALF和LFmRNA水平的定量检测 斯坦福大学收集的具有特征性的存档乳腺肿瘤标本 大学医院。然后，我们将把我们的结果与各种 临床参数包括肿瘤分级、组织学、有无 雌激素受体和患者年龄。我们将采取谨慎措施确保 肿瘤标本的匿名。检测ALF或LFmRNA可能是有用的 作为乳腺癌的分子标记，选择更多可能是有益的 积极的手术程序、治疗方案或在确定 预后。 建议的商业应用： 如果拟议的第一阶段和第二阶段研究成功，并且ALF是 被确定为通用的II类肿瘤抑制基因，一个定量的 ALF信使核糖核酸的测定将在基础研究中作为一种 基特。此外，如果ALF是乳腺癌的有用分子标记物，我们 会将化验授权给诊断界。

Lactoferrin, which is an iron binding protein present in milk and various secretions, has emerged as a multifunctionai protein involved in the host defense against infection and tumorogenesis. We have recently identified an alternative form of LF mRNA we term ALF. Although, we find ALF mRNA in 100% (30 of 30) normal human tissues, we find ALF mRNA in only 10% (3 of 28) diverse tumor-derived cell lines. In a preliminary study, we found lower levels of ALF mRNA in 90% (9 of 10) primary breast tumor specimens compared to normal human breast tissues. In Phase I, we plan to develop a quantitative RT-PCR assay for both LF and LF mRNA. We will then quantitatively examine levels of ALF and LF mRNA in 142 fully characterized, archived breast tumor specimens collected at Stanford University Hospital. We will then correlate our results to various clinical parameters including tumor grade, histology, presence or absence of estrogen receptors, and patient age. Care will be taken to ensure anonymity of tumor specimens. Measurement of ALF or LF mRNA may be useful as a molecular marker in breast cancer and may be beneficial choosing more aggressive surgical procedures, treatment options, or in determining prognosis. PROPOSED COMMERCIAL APPLICATION: If the proposed Phase I and Phase II study is successful, and ALF is established as a general Class II tumor-suppressor gene, a quantitative assay to measure ALF mRNA will be widely useful in basic research as a kit. Further, if ALF is an useful molecular marker for breast cancer, we would license the assay to the diagnostic community.